Table 2.
Number of patients with each symptom at baseline
| Omeprazole group (n = 139) | Famotidine group (n = 129) | Mosapride group (n = 118) | Teprenone group (n = 68) | |||||
|---|---|---|---|---|---|---|---|---|
|
Stomach pain |
87 |
(14.6) |
90 |
(17.5) |
74 |
(15.2) |
51 |
(16.1) |
|
Heartburn |
89 |
(15.0) |
75 |
(14.6) |
64 |
(13.1) |
43 |
(13.6) |
|
Regurgitation |
66 |
(11.1) |
54 |
(10.5) |
60 |
(12.3) |
35 |
(11.1) |
|
Postprandial fullness |
113 |
(19.0) |
100 |
(19.5) |
87 |
(17.9) |
55 |
(17.4) |
|
Vomiting |
59 |
(9.9) |
51 |
(9.9) |
54 |
(11.1) |
29 |
(9.2) |
|
Belching |
46 |
(7.7) |
31 |
(6.0) |
34 |
(7.0) |
30 |
(9.5) |
|
Early satiety |
60 |
(10.1) |
47 |
(9.2) |
51 |
(10.5) |
33 |
(10.4) |
| Bloating | 75 | (12.6) | 65 | (12.7) | 63 | (12.9) | 40 | (12.7) |
Values are n (%). There were no significant differences in rates of each symptom across treatment groups (all, p > 0.05).